FFAR1介导PPARγ激动剂拮抗β细胞脂毒性损害的分子机制

基本信息
批准号:81270940
项目类别:面上项目
资助金额:16.00
负责人:杨立勇
学科分类:
依托单位:福建医科大学
批准年份:2012
结题年份:2013
起止时间:2013-01-01 - 2013-12-31
项目状态: 已结题
项目参与者:沈喜妹,吴佩文,严孙杰,黄林晶,陈丹玲,郑玲容
关键词:
胰岛β细胞氧化应激游离脂肪酸受体1PPARγ激动剂脂毒性
结项摘要

It is the core pathway to block β cells lipotoxicity-induced damage for preventing and treating diabetes, but it still lacks of specific intervention to lipotoxicity. In our present study, we have found that down-regulating the expression of free fatty acid receptor-1 (FFAR1) can weaken the anti-lipotoxicity effect of PPARγ agonist Pioglitazone(Piog) on β cells. Our results indicate that FFAR1 might mediate the anti-lipotoxicity role of PPARγ agonist. In order to confirm the hypothesis above, this project is designed to set β cell lines as an object of research, use RNAi and gene overexpression to regulate gene expression, regulate protein activity by chemicals in functional protein level, and build the cell model of exogenous FFAR1 expression with FFAR1 negative cell lines for an in-depth study of the potential role of FFAR1 through the three steps as follows: at first, our project is planned to observe whether FFAR1 mediates the anti-lipotoxicity effect of Piog; and next, we will analyze whether the possible pathway mediated by FFAR1 is by way of regulating the activity and expression of PPARγ, inhibiting oxidative stress, and improving the expression of insulin-related genes such as PDX-1 and MafA; at last, we will further investigate whether the effect of FFAR1 is conducted by the PLC-IP3-Ca2+ pathway from the perspective of molecular mechanisms. This project is with the purpose of providing a new way or target for intervening in β-cell lipotoxicity damage.

阻断β细胞脂毒性损害始终是防治糖尿病的核心,但迄今缺乏靶向干预药物。我们前期研究发现下调游离脂肪酸受体1(FFAR1)表达将削弱PPARγ激动剂Pioglitazone(Piog)拮抗β细胞脂毒性的作用,推测FFAR1可能参与Piog的抗脂毒性机制。为此,本研究拟以胰岛β细胞系为研究对象,采用RNA干扰和基因过表达技术调控基因表达;运用干预制剂在功能蛋白层面直接调节蛋白活性;利用FFAR1阴性表达细胞构建外源性FFAR1表达细胞模型等手段,从以下三个层次深入剖析FFAR1的潜在作用:首先观察FFAR1是否介导Piog的抗脂毒性作用;接着分析FFAR1介导作用的可能途径是否通过调节核因子PPARγ表达及活性,抑制氧化应激,改善胰岛素相关基因MafA、PDX-1的表达;最后从分子机制角度探讨FFAR1发挥效应是否经PLC-IP3-Ca2+通路传导。以期为干预β细胞脂毒性损害提供新的途径或靶点。

项目摘要

阻断β细胞脂毒性损害始终是防治糖尿病的核心,但迄今缺乏靶向干预药物。我们前期研究发现下调游离脂肪酸受体1(FFAR1)的表达将削弱PPARγ激动剂Pioglitazone(PIO)拮抗β细胞脂毒性的作用,推测FFAR1可能参与Piog的抗脂毒性机制。为此,本研究以胰岛β细胞系为研究对象,采用RNA干扰和基因过表达技术调控FFAR1基因表达,观察FFAR1不同表达水平对PIO 抗脂毒性作用的影响及可能途径。结果显示:FFAR1可通过介导抗氧化应激参与PIO抑制β细胞脂性凋亡的作用,相关机制可能涉及到PLCγ-IP3-ERK1/2-PPARγ途径的活化。我们的研究结果不仅有助于区分FFAR1在脂毒性中扮演的角色,而且还为拮抗β细胞脂毒性的损害提供了实验证据,同时有助于了解PIO作为FFAR1的激动剂减弱胰岛β细胞脂性凋亡的相关分子机制。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

Intensive photocatalytic activity enhancement of Bi5O7I via coupling with band structure and content adjustable BiOBrxI1-x

Intensive photocatalytic activity enhancement of Bi5O7I via coupling with band structure and content adjustable BiOBrxI1-x

DOI:10.1016/j.scib.2017.12.016
发表时间:2018
2

Asymmetric Synthesis of (S)-14-Methyl-1-octadecene, the Sex Pheromone of the Peach Leafminer Moth

Asymmetric Synthesis of (S)-14-Methyl-1-octadecene, the Sex Pheromone of the Peach Leafminer Moth

DOI:
发表时间:
3

七羟基异黄酮通过 Id1 影响结直肠癌细胞增殖

七羟基异黄酮通过 Id1 影响结直肠癌细胞增殖

DOI:
发表时间:
4

2016年夏秋季南极布兰斯菲尔德海峡威氏棘冰鱼脂肪酸组成及其食性指示研究

2016年夏秋季南极布兰斯菲尔德海峡威氏棘冰鱼脂肪酸组成及其食性指示研究

DOI:10.13679/j.jdyj.20190001
发表时间:2020
5

Sparse Coding Algorithm with Negentropy and Weighted ℓ1-Norm for Signal Reconstruction

Sparse Coding Algorithm with Negentropy and Weighted ℓ1-Norm for Signal Reconstruction

DOI:10.3390/e19110599
发表时间:2017

相似国自然基金

1

PPARδ通过上调GLP-1受体抗胰岛β细胞脂毒性凋亡的分子机制研究

批准号:81170777
批准年份:2011
负责人:童南伟
学科分类:H0708
资助金额:58.00
项目类别:面上项目
2

FOXO1的双重作用介导Ghrelin 拮抗胰岛β细胞脂毒性和调控胰岛素分泌功能的分子机制研究

批准号:81471081
批准年份:2014
负责人:王威
学科分类:H0710
资助金额:65.00
项目类别:面上项目
3

PPARα介导共轭亚油酸(CLA)降低草鱼肝脂积累的分子机制研究

批准号:31672666
批准年份:2016
负责人:董桂芳
学科分类:C1905
资助金额:62.00
项目类别:面上项目
4

ACSL亚型在脂毒性胰岛beta细胞功能损害中的作用及其调节

批准号:30971078
批准年份:2009
负责人:赵玉峰
学科分类:C1102
资助金额:31.00
项目类别:面上项目